Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 2, 1998, Pages 220-224

  Parsons, Andrew A ^a   Raval, Pravin ^a   Smith, Susan ^a   Tilford, Nick ^a   King, Frank D ^a   Kaumann, Alberto J ^b   Hunter, Jackie ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

5 HT(1B 1D) receptors; Basilar artery; Coronary artery; Frovatriptan; Human; Migraine

Indexed keywords

FROVATRIPTAN; NARATRIPTAN; RIZATRIPTAN; SEROTONIN 1 AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ARTERY CONSTRICTION; ARTICLE; BASILAR ARTERY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN TISSUE; MIGRAINE; PRIORITY JOURNAL;

BASILAR ARTERY; CARBAZOLES; CORONARY CIRCULATION; HUMANS; LIGANDS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SUMATRIPTAN; TRYPTAMINES; VASOCONSTRICTOR AGENTS;

EID: 0031857853     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199808000-00008     Document Type: Article

References (37)

1. Pilgrim AJ. The clinical profile of sumatriptan: efficacy in migraine. Eur Neurol 1994;34:26-34.
2. Pilgrim AJ, Blakebourough P. The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemp Pharmacother 1994;5:295-309.
3. Visser WH, de Vriend RHM, Jaspers NWH, Ferrari MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 1996;47:46-51.
4. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD. Rizatriptan vs sumatriptan in the acute treatment of migraine. Arch Neurol 1996;53:1132-7.
5. 1D receptor agonist in the acute treatment of migraine: a double-blind, placebo-controlled, dose ranging study. Neurology 1996;46:522-6.
6. Farkkila M. A dose finding study of eletriptan (UK-116,044) (5-30 mg) for the acute treatment of migraine. Cephalalgia 1996;16:387.
7. Mathew MT. Efficacy and tolerability of naratriptan tablets in the treatment of migraine: results of a double-blind, placebo-controlled, crossover trial. Neurology 1997;48:A85.
8. Dahlof C. Randomized, double-blind, placebo-controlled comparison of oral naratriptan and oral sumatriptan in the acute treatment of migraine. Neurology 1997;48:A85.
9. 1B/1D agonist for the treatment of acute migraine. Cephalalgia 1997;17:418.
10. Humphrey PPA, Goadsby PJ. The mode of action of sumatriptan is vascular? A debate. Cephalalgia 1994;14:401-10.
11. 1-like receptors in rabbit isolated basilar arteries. Eur J Pharmacol 1989;174:189-96.
12. 1-like receptor agonist. Br J Pharmacol 1989;96:379-87.
13. 1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br J Pharmacol 1989;96:434-49.
14. Janssen I, Olesen J, Edvinsson L. 5-Hydroxytryptamine receptor characterization of human cerebral, middle meningeal and temporal arteries: regional differences. Acta Physiol Scand 1993;147: 141-50.
15. Humphrey PPA, Feniuk W, Motevalian M, Parsons AA, Whalley ET. The vasoconstrictor action of sumatriptan on human isolated dura mater. In: Fozard JR, Saxena PR. ed. Serotonin: molecular biology and functional effects. Basel: Birkhauser, 1991:421-9.
16. 1-like receptor in dog isolated saphenous vein. Br J Pharmacol 1988;94:1123-32.
17. 2 receptor activation. Eur J Pharmacol 1988;161:91-4.
18. 2 receptors in serotonin-induced contraction of human isolated coronary arteries. Circulation 1994;90:114-53.
19. Perren MJ, Feniuk W, Humphrey PPA. The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR 43175. Cephalalgia 1989;9(suppl 9):41-6.
20. Feniuk W, Humphrey PPA, Perren MJ. The selective carotid arterial vasoconstrictor action of GR 43175 in anaesthetized dogs. Br J Pharmacol 1989;96:83-90.
21. 1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol 1991;102:323-30.
22. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in the dura mater. Br J Pharmacol 1990;99: 202-6.
23. 1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 1997;121:157-64.
24. Connor HE, Feniuk W, Beattie DT, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997;17:145-52.
25. 1B/1D receptor agonist, in experimental model predictive of antimigraine activity and coronary side-effect potential. Naunyn Schmiedebergs Arch Pharmacol 1997;355:295-302.
26. 3]alniditan. Mol Pharmacol 1996;50:1567-80.
27. Ferro A, Longmore J, Hill RG, Brown MJ. A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vitro. Br J Clin Pharmacol 1995;40:245-51.
28. 1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br J Clin Pharmacol 1996;42:431-41.
29. MassenvandenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Current and future anti-migraine drugs in the human isolated coronary artery. Br J Pharmacol 1997;120:68P.
30. 1D receptors. Br J Pharmacol 1996;119:110P.
31. Bax WA, Renzenbrink GJ, vanHeuven-Nolsen D, Thijssen EJM, Bos E, Saxena PR. 5-HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharmacol 1993;239:203-10.
32. Kaumann AJ, Parsons AA, Brown AM. Human arterial constrictor 5-HT receptors. Cardiovasc Res 1993;27:2094-103.
33. Hamel E, Fan E, Linville D, Tong V, Villemure J-G, Chia L-S. Expression of mRNA for the serotonin 5-hydroxytryptamine (1D beta) receptor subtype in human and bovine cerebral arteries. Mol Pharmacol 1993;44:242-6.
34. Cushing DJ, Zgombick JM, Nelson DL, Cohen ML. LY215840, a high affinity 5-HT7 receptor ligand, blocks serotonin-induced relaxation in canine coronary artery. J Pharmacol Exp Ther 1995; 277:1560-6.
35. 7 serotonin receptor subtype. J Biol Chem 1993;268:18200-4.
36. 7) positively linked to adenylate cyclase. J Biol Chem 1993;268: 23422-6.
37. 1B/1D receptor agonist, SB-209509 (VML251), and sumatriptan in dogs. J Cardiovasc Pharmacol 1997;30:136-41.